Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ABT-700 |
Synonyms | |
Therapy Description |
ABT-700 (h224G11) is a bivalent monoclonal antibody that targets c-MET and inhibits activation of downstream signaling, potentially decreasing the growth of MET amplified tumors (PMID: 23134362, PMID: 32127466). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ABT-700 | h224G11|Telisotuzumab|ABT 700|ABT700 | MET Antibody 31 | ABT-700 (h224G11) is a bivalent monoclonal antibody that targets c-MET and inhibits activation of downstream signaling, potentially decreasing the growth of MET amplified tumors (PMID: 23134362, PMID: 32127466). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01472016 | Phase I | Docetaxel ABT-700 Cetuximab Erlotinib Fluorouracil + Irinotecan + Leucovorin | Study of ABT-700 in Subjects With Advanced Solid Tumors | Completed | 0 |